Search results | gastrointestinal

Reports

Gastrointestinal Symptoms Partnering

The Gastrointestinal Symptoms Partnering report provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

Gastrointestinal Partnering Terms and Agreements

The Gastrointestinal Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Salix Pharmaceuticals – Getting to grips with gastrointestinal disorders

Specialty Pharmaceuticals Company Salix Pharmaceuticals is committed to providing treatments for a wide spectrum of gastrointestinal disorders.

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Salix Pharmaceuticals: Partnering activity 2009-2014

Salix Pharmaceuticals is a leading specialty pharmaceutical company, listed in the top 50 big biotech list by Current Partnering.

Salix Pharmaceuticals: M&A activity 2009 – 2014

Salix Pharmaceuticals has announced 3 M&A deals since 2009, with the deals being the acquisition of Santarus, Oceana Therapeutics and the merger between Salix and Cosmo Pharmaceuticals.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

NPS Pharmaceuticals: Big biotech partnering trends 2009-2014

NPS Pharmaceuticals is a US based specialty company. The company mainly focuses its efforts to treat rare diseases worldwide. 

NPS Pharmaceuticals – developing and partnering for rare diseases

NPS Pharmaceuticals is a global pharmaceutical company treating rare diseases specifically focusing upon gastrointestinal and endocrine disorders.

Q2 Partnering and Licensing Pharma trends of 2014

July 2014 By Raveena Bhambra Q2 was full of deals, coupled with the talk of potential deals, and overall it finished on a high with a large volume of agreements coming together in June.

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Abbvie: Partnering activity 2009-2014

Abbvie, a top global biopharmaceutical company headquartered in the United States, focusses on solving threatening health problems. A recently formed company in 2013, Abbvie was formed as a separate research based pharma company from Abbott.

Events

Sorry, your search returned no results.


Deals

Lyric Pharma grabs $20.4m series A financing

Lyric Pharmaceuticals announced the initial closing of a Series A financing round totaling $20.4 million

Shire acquires Meritage Pharma for $70 million

Shire has acquired Meritage for an upfront fee of $70 million and additional contingent payments

Valeant acquires Salix Pharma for $14.5 billion

Valeant Pharmaceuticals have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix

Shire moves to acquire NPS Pharma

Shire and NPS Pharmaceuticals have entered into a merger agreement pursuant to which Shire will acquire all the outstanding shares of NPS Pharma for $46.00 per share in cash, for a total consideration of approximately $5.2 billion

Janssen and Isis in RNA-targeted therapeutics pact

Isis Pharmaceuticals has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract

Jaguar Animal Health headed towards $70m IPO financing

Financing news: The veteran of two biotech companies — Napo Pharmaceuticals Inc. and Shaman Pharmaceuticals Inc. — is leading a new company toward a planned $70 million initial public offering .

Big pharma, Mylan, buys generic business from Abbott

Mylan, big pharma, will acquire Abbott’s non-U.S. developed markets specialty and branded generics business (“the Assets”) in an all-stock transaction.

Lumena has been acquired by Shire

Shire and Lumena Pharmaceuticals announce the acquisition of Lumena Pharmaceuticals by Shire.

Seattle Genetics gets $6 million in milestone from pharma deal

Seattle Genetics gets $6 million in milestone payment from a pharma deal with Takeda.

Ironwood prices public offering financing for $175 million

Ironwood Pharmaceuticals announced the pricing of an underwritten public offering financing of 13,725,500 shares of its Class A common stock at a price of $12.75 per share to the public.